  
 **4th Annual HFC Gastrointestinal & Neuroendocrine Multidisciplinary Symposium (4/25/2025) | 04/25/2025 7:00 AM The Henry Hotel**

Gastrointestinal and Neuroendocrine symposium that provides the latest information in a multidisciplinary format. Updating clinical teams on the latest GI and Neuroendocrine Oncology topics including information on Germline Mutations, ctDNA Testing, Localized Pancreatic Cancer, Biliary Cancers, Metastatic Colorectal Cancers, Immunotherapies and other topics.

**Program Goal**

1 To understand the impact of recent data from clinical trials for GI and NET cancer patient care.

2 To become informed on best practices in an integrated multimodality thereapy for patients with GI cancers and NET tumors.

3 To use molecular diagnostic studies in the management of patients with GI and NET tumors.

**Target Audience** Hematology / Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sumit Singla, MD | Faculty | Consulting Fee-Boston Scientific - 09/23/2024 |
| Dhananjay Chitale, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Natera Inc Com (Relationship has ended) - 01/08/2025 |
| David Kwon, MD | Faculty | Nothing to disclose - 01/17/2025 |
| Gazala Khan, MD | Faculty | Nothing to disclose - 01/14/2025 |
| Reena Salgia, MD, FAASLD | Faculty | Advisor-Eisai (Relationship has ended)|Advisor-Exelixis (Relationship has ended)|Advisor-Astrazeneca (Relationship has ended)|Advisor-Cook Medical (Relationship has ended) - 01/15/2025 |
| Parag Parikh, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Nuvaira - 01/13/2025 |
| Asfar S Azmi, PhD | Faculty | Grant or research support-Colorado Chromatography, Blackstone Therapeutics, TyrNovo Therapeutics, RLL Pharmaceuticals (Relationship has ended) - 01/08/2025 |
| Surya Nalamati, MD | Faculty | Nothing to disclose - 01/16/2025 |
| Crystal M Gyiraszin, MS | CME Reviewer |  |
| Denise Brooks, MBA | CME Specialist | Nothing to disclose - 11/27/2024 |
| Tressa Cuschieri, BBA | Activity Coordinator | Nothing to disclose - 12/04/2024 |
| Philip Philip, MD, PhD | Course Director, Faculty | Consulting Fee-Advisor, Speaker Beureau, |Grant or research support-Karyopharm (Relationship has ended)|Advisor-Pfizer|Advisor-Seattle Genetics|Consulting Fee-Bayer|Grant or research support-Carcept (Relationship has ended)|Honoraria-Daiichi (Relationship has ended)|Honoraria-Erytech (Relationship has ended)|Honoraria-Incyte|Honoraria-Ipsen (Relationship has ended)|Honoraria-Merck (Relationship has ended)|Honoraria-Novocure (Relationship has ended)|Grant or research support-Rafael (Relationship has ended)|Honoraria-Genetech (Relationship has ended)|Consulting Fee-Trisauls (Relationship has ended)|Advisor-Boston Pharmaceuticals (Relationship has ended)|Honoraria-Servier (Relationship has ended) - 12/11/2024 |
| Anthony Shields, MD, PhD | Faculty | Other: Dr. Shields has no equity or financial interest in TheraBionic, Inc. and receives no direct support from the company. Dr. Boris Pasche is the current President and CEO of Karmanos Cancer Institute. The TheraBionic device was developed by Dr. Pasche and he serves as CEO, Board Chair and Co-Founder, as well as being an investor.-TheraBionic - 01/29/2025 |
| Ulka Vaishampayan, MD | Faculty | Grant or research support-Merck, BMS|Consulting Fee- Astellas, Mural, Merck, Exelixis, Gilead, Novartis, BMS, Pfizer, Bayer|Honoraria-Exelixis, Sanofi, Bayer, Pfizer - 01/12/2025 |
| Katherine Cools, MD | Faculty | Nothing to disclose - 01/08/2025 |
| Ahmed Kaseb, MD | Faculty | Honoraria-BMS|Consulting Fee-BMS|Honoraria-Genentech|Consulting Fee-Genentech|Honoraria-Astrazeneca|Consulting Fee-Astrazeneca|Honoraria-Eisai|Consulting Fee-Eisai|Honoraria-Exelixis|Consulting Fee-Exelixis|Grant or research support-BMS|Grant or research support-Genentech|Grant or research support-Astrazeneca|Grant or research support-Eisai|Grant or research support-Exelixis|Grant or research support-Adaptimmune|Grant or research support-Tvardi - 01/08/2025 |
| Sreenivasa Chandana, MD | Faculty | Grant or research support-AbbVie|Grant or research support-Adcentrx Therapeutics|Grant or research support-Amgen|Grant or research support-Astrazeneca|Grant or research support-Cardiff Oncology |Grant or research support-Dicephera |Grant or research support-Elevation Oncology|Grant or research support-Exact Sciences|Grant or research support-Roche|Grant or research support-IDEAYA Biosciences|Grant or research support-IGM Biosciences|Grant or research support-Janssen|Grant or research support-Incyte|Grant or research support-Ipsen|Grant or research support-Merck|Grant or research support-Mirati |Grant or research support-Novocure|Speakers Bureau-Natera|Grant or research support-Qualigen Therapeutics |Grant or research support-Zyme Works |Grant or research support-BMS|Advisor-IPSEN |Speakers Bureau-Natera - 01/30/2025 |
| Maria Diab, MD | Faculty | Advisor-Novartis|Advisor-Astrazeneca (Relationship has ended) - 01/15/2025 |
| Mohammed Najeeb Al Hallak, MD | Faculty | Speakers Bureau-Astrazeneca|Speakers Bureau-Guardant Health|Speakers Bureau-Ipsen (Relationship has ended)|Speakers Bureau-Seagen (Relationship has ended) - 01/19/2025 |
| Anwaar Saeed, MD, Associate Professor | Faculty | Consulting Fee-Astrazeneca|Consulting Fee-Autem therapeutics |Consulting Fee-Replimune |Consulting Fee-Amgen|Grant or research support-Replimune |Grant or research support-Arcus therapeutics |Grant or research support-Phanes therapeutics |Consulting Fee-Xilio Therapeutics |Consulting Fee-Jazz therapeutics (Relationship has ended)|Consulting Fee-Exelixis|Consulting Fee-Taiho Pharmaceutical (Relationship has ended)|Consulting Fee-Merck (Relationship has ended)|Consulting Fee-BMS|Grant or research support-Astrazeneca|Grant or research support-BMS|Grant or research support-Clovis Oncology|Grant or research support-Exelixis|Grant or research support-Merck|Grant or research support-KAHR Medical |Grant or research support-Incyte Corporation |Consulting Fee-Arcus Therapeutics |Grant or research support-Oxford Biotherapeutics |Grant or research support-Actuate Therapeutics - 01/07/2025 |
| Van K. Morris, MD | Faculty | Advisor-Pfizer|Consulting Fee-BMS (Relationship has ended)|Advisor-Scandion Oncology (Relationship has ended)|Advisor-Incyte (Relationship has ended)|Advisor-Novartis (Relationship has ended)|Grant or research support-BMS|Grant or research support-AmMax Bio|Grant or research support-Pfizer|Grant or research support-BioNTech - 01/17/2025 |
| Richard Berri, MD | Faculty | Nothing to disclose - 01/30/2025 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 6.00 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

ABIM MOC Part 2: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Tressa Cuschieri at TCUSCHI1@hfhs.org If you have questions, please email Tressa Cuschieri at TCUSCHI1@hfhs.org. Please allow a minimum of 3 days to process this request.